BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

[email protected]

[email protected]

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Piyasa Fırsatı
FLOW Logosu
FLOW Fiyatı(FLOW)
$0.1757
$0.1757$0.1757
-0.45%
USD
FLOW (FLOW) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Top Altcoins To Hold Before 2026 For Maximum ROI – One Is Under $1!

Top Altcoins To Hold Before 2026 For Maximum ROI – One Is Under $1!

BlockchainFX presale surges past $7.5M at $0.024 per token with 500x ROI potential, staking rewards, and BLOCK30 bonus still live — top altcoin to hold before 2026.
Paylaş
Blockchainreporter2025/09/18 01:16
Best Crypto to Buy as Saylor & Crypto Execs Meet in US Treasury Council

Best Crypto to Buy as Saylor & Crypto Execs Meet in US Treasury Council

The post Best Crypto to Buy as Saylor & Crypto Execs Meet in US Treasury Council appeared on BitcoinEthereumNews.com. Michael Saylor and a group of crypto executives met in Washington, D.C. yesterday to push for the Strategic Bitcoin Reserve Bill (the BITCOIN Act), which would see the U.S. acquire up to 1M $BTC over five years. With Bitcoin being positioned yet again as a cornerstone of national monetary policy, many investors are turning their eyes to projects that lean into this narrative – altcoins, meme coins, and presales that could ride on the same wave. Read on for three of the best crypto projects that seem especially well‐suited to benefit from this macro shift:  Bitcoin Hyper, Best Wallet Token, and Remittix. These projects stand out for having a strong use case and high adoption potential, especially given the push for a U.S. Bitcoin reserve.   Why the Bitcoin Reserve Bill Matters for Crypto Markets The strategic Bitcoin Reserve Bill could mark a turning point for the U.S. approach to digital assets. The proposal would see America build a long-term Bitcoin reserve by acquiring up to one million $BTC over five years. To make this happen, lawmakers are exploring creative funding methods such as revaluing old gold certificates. The plan also leans on confiscated Bitcoin already held by the government, worth an estimated $15–20B. This isn’t just a headline for policy wonks. It signals that Bitcoin is moving from the margins into the core of financial strategy. Industry figures like Michael Saylor, Senator Cynthia Lummis, and Marathon Digital’s Fred Thiel are all backing the bill. They see Bitcoin not just as an investment, but as a hedge against systemic risks. For the wider crypto market, this opens the door for projects tied to Bitcoin and the infrastructure that supports it. 1. Bitcoin Hyper ($HYPER) – Turning Bitcoin Into More Than Just Digital Gold The U.S. may soon treat Bitcoin as…
Paylaş
BitcoinEthereumNews2025/09/18 00:27
Why Blazpay and TRON Are the Best Coin to Buy Now According to 2025 Predictions

Why Blazpay and TRON Are the Best Coin to Buy Now According to 2025 Predictions

Phase 5 of the Blazpay presale is live now, ending soon, and early investors are already noticing the explosive potential of this presale token. With TRON (TRX)
Paylaş
Techbullion2025/12/20 17:12